Cara Therapeutics Inc (CARA)
NASDAQ
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 23M | 10.81M | 3.26M | 6.17M | 6.93M | 4.87M | 3M | 2.14M |
| Operating Income | -4.47M | -23.85M | -31.31M | -27.65M | -32.34M | -28.9M | -32.61M | -29.67M |
| Pre Tax Income | -4.21M | -23.18M | -30.34M | -26.67M | -31.48M | -28.03M | -32.34M | -30.7M |
| Net Income | -4.21M | -23.18M | -30.34M | -26.67M | -31.48M | -28.03M | -32.34M | -30.7M |
| Preferred Dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic Earnings Per Share (EPS) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -4.21M | -23.18M | -30.34M | -26.67M | -31.48M | -28.03M | -31.73M | -28.71M |
| EBITDA | -4.41M | -23.78M | -31.25M | -27.59M | -32.28M | -28.84M | -32.53M | -29.62M |
| Year End December 30 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 86k | 911k | 13.47M | 19.89M | 135.08M | 23.03M | 41.87M | 20.97M |
| Operating Income | -58.4M | -59.49M | -77.38M | -111.68M | 5.39M | -89.08M | -87.54M | -121.5M |
| Pre Tax Income | -57.75M | -58.33M | -74.4M | -107.19M | 7.72M | -88.44M | -85.47M | -118.51M |
| Net Income | -57.28M | -58.13M | -74.01M | -106.37M | 8.41M | -88.44M | -85.47M | -118.51M |
| Preferred Dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic Earnings Per Share (EPS) | -2.098 | -1.78 | -1.871 | -2.277 | 0.169 | -1.654 | -1.589 | -2.175 |
| EBIT | -57.75M | -58.33M | -74.4M | -107.19M | 7.72M | -88.44M | -85.47M | -117.91M |
| EBITDA | -56.94M | -58.99M | -77.01M | -111.48M | 5.59M | -88.84M | -87.29M | -121.24M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
